Details for Patent: 12,509,684
✉ Email this page to a colleague
Which drugs does patent 12,509,684 protect, and when does it expire?
Patent 12,509,684 protects TRYNGOLZA (AUTOINJECTOR) and is included in one NDA.
This patent has two hundred and sixty-one patent family members in forty countries.
Summary for Patent: 12,509,684
| Title: | Compositions and methods for modulating apolipoprotein C-III expression |
| Abstract: | Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof. |
| Inventor(s): | Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham |
| Assignee: | Ionis Pharmaceuticals Inc |
| Application Number: | US18/417,807 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 12,509,684
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-002 | Jun 24, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | USE IN REDUCING TRIGLYCERIDES AND THE RISK OF ACUTE PANCREATITIS IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG: TG GREATER THAN OR EQUAL TO 500 MG/DL) | ⤷ Start Trial | ||||
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-001 | Dec 19, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | USE IN REDUCING TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) | ⤷ Start Trial | ||||
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-001 | Dec 19, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | USE IN REDUCING TRIGLYCERIDES AND THE RISK OF ACUTE PANCREATITIS IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG: TG GREATER THAN OR EQUAL TO 500 MG/DL) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,509,684
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3524680 | ⤷ Start Trial | CA 2025 00027 | Denmark | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | C20250028 | Finland | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | 301341 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | 122025000044 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
